Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Other Non-Current Liabilities (2016 - 2025)

Avanos Medical's Other Non-Current Liabilities history spans 9 years, with the latest figure at $10.5 million for Q2 2024.

  • For Q2 2024, Other Non-Current Liabilities changed N/A year-over-year to $10.5 million; the TTM value through Jun 2024 reached $10.5 million, changed N/A, while the annual FY2023 figure was $10.0 million, 51.22% down from the prior year.
  • Other Non-Current Liabilities for Q2 2024 was $10.5 million at Avanos Medical, down from $10.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $20.5 million in Q4 2022 and bottomed at $9.1 million in Q4 2021.
  • The 5-year median for Other Non-Current Liabilities is $10.6 million (2024), against an average of $12.0 million.
  • The largest annual shift saw Other Non-Current Liabilities skyrocketed 125.27% in 2022 before it crashed 51.22% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $11.0 million in 2020, then fell by 17.27% to $9.1 million in 2021, then surged by 125.27% to $20.5 million in 2022, then plummeted by 51.22% to $10.0 million in 2023, then rose by 5.0% to $10.5 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Other Non-Current Liabilities are $10.5 million (Q2 2024), $10.8 million (Q1 2024), and $10.0 million (Q4 2023).